Non-Executive Chairman
Brian Jamieson FCA
Mr Jamieson was Chief Executive of Minter Ellison Melbourne and a partner of the Minter Ellison Revenue Group from 2002-2005. He retired as Chief Executive of Minter Ellison Melbourne on 31 December 2005. Prior to joining Minter Ellison, Mr Jamieson was Executive Officer at KPMG Australia from 1998-2000, Managing Partner of KPMG Melbourne and Southern Regions from 1993-1998 and Chairman of KPMG Melbourne from 2001-2002. He was also a KPMG Board Member in Australia, and a member of the USA Management Committee. Mr Jamieson has over 30 years of experience in providing advice and audit services to a diverse range of public and large private companies. He is a fellow of the Institute of Chartered Accountants in Australia.
Other current directorships
Chairman, Sigma Pharmaceuticals Limited
Non-Executive Director, Tatts Group Limited
Non-Executive Director, OZ Minerals Limited
Non-Executive Director, Tigers Realm Coal Limited
Director and Treasurer, Bionics Institute
Director and Treasurer, The Sir Robert Menzies Foundation
Chief Executive Officer
Professor Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR
Professor Itescu has established an outstanding international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He is currently an active faculty member of the University of Melbourne and Monash University and was previously a faculty member of Columbia University in New York. Professor Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of a number of publicly-listed life sciences companies.
Other current directorships
Director of Mesoblast Inc.
Non-Executive Director
Donal O’Dwyer, BE, MBA
Mr O’Dwyer has over 20 years’ experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, Mr O’Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its president (Europe) and from 2000 as its worldwide president. In his role, Mr O’Dwyer led Cordis through the launch of the revolutionary Cypher drug eluting coronary stent technology, and saw the company take over number one market share of coronary stents worldwide. Prior to joining Cordis, Mr O’Dwyer worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. Mr O’Dwyer is a qualified civil engineer and has an MBA.
Other current directorships
Non-Executive Director, Cochlear Limited
Non-Executive Director, Atcor Medical Holdings Limited
Chairman, Atcor Medical Pty Ltd
Non-Executive Director, Sunshine Heart Inc.
Chairman, Endoluminal Sciences Pty Ltd
Non-Executive Director
Michael Spooner, BCom, ACA, MAICD
Mr Spooner is a well-known and respected business leader. He has an extensive network of relationships with investment firms and business communities across the globe, having spent the majority of the past 25 years living and working internationally. Mr Spooner consults to a number of listed and unlisted companies based in Australia and the United States. In 2009 Mr Spooner was appointed Chairman of BiVACOR a total artificial heart company. Most recently, Mr Spooner was a non-executive director of Peplin Inc., a dermatology focused skin cancer company from 2004 until the company was sold in 2009 for over $300m. He was also a non-executive director of Hawaii Biotech Inc. a specialty developer of vaccines from 2010 to 2011. Previously, Mr Spooner was the Chairman of Mesoblast Limited from its initial listing in 2004 until 2007 and Managing Director & CEO of Ventracor Limited where he led the transformation of a small Australian listed life sciences company into the second highest performing stock on the S&P/ASX 200 index. He was a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong for several years.
Other current directorships
Chairman, BiVACOR Pty Ltd
Non-Executive Director
Ben-Zion Weiner, BSc, MSc, PhD
Dr Weiner was Teva’s head of global research and development for over three decades, most recently as Chief R&D Officer and a member of the Teva Executive Committee. In this role, he directly oversaw all pharmaceutical R&D and innovative branded product pipeline development. Dr Weiner has been responsible for the development of hundreds of generic products for the United States, European and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva’s innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis.
Other current directorships
Director, Gefen Biomed Investments Ltd
Company Secretary
Jenni Pilcher CA, BBS
Since qualifying as a Chartered Accountant with Price Waterhouse, Mrs Pilcher has worked in corporate and business financial roles for high profile international companies in pharmaceuticals, FMCG (fast moving consumer goods) and services. Before joining Mesoblast as Financial Controller in 2007, she spent six years with ASX 200 Company, Spotless Group, progressing through a variety of financial roles. Previously Mrs Pilcher worked in the finance teams at Cadbury Schweppes plc and international pharmaceutical group Medeva plc, both based in the United Kingdom. She was appointed Chief Financial Officer of Mesoblast in November 2007 and Company Secretary in January 2012.